Suchergebnisse - "Ofran, Yishai"

PubPharm (5)

1

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE) : part one of a randomised, phase 2, dose optimisation study

enthalten in: The Lancet. Haematology | 2023

von Pabst, T. | Papayannidis, C. | Demirkan, F. | +23

CommentIn: Lancet Haematol. 2023 Nov;10(11):e868-e870. - PMID 37914475

2

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia : An open-label safety and efficacy phase 2a study

enthalten in: Cancer | 2021

von Borthakur, G. | Ofran, Y. | Tallman, M. | +27

3

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy : results from a multicenter, randomized, phase 2/3 study

enthalten in: Leukemia | 2021

von Montesinos, P. | Roboz, G. | Bulabois, C. | +22

4

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction : a phase 1/2a study

enthalten in: Blood advances | 2019

von Zuckerman, T. | Ram, R. | Akria, L. | +14

5

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

enthalten in: Annals of hematology | 2016

von Mittelman, M. | Filanovsky, K. | Ofran, Y. | +10

1
[1]